Healio Minute

In this edition, prior authorization linked delay in prescription fills; disparities in access to specialized cancer centers; ‘new potential treatment option’ for advanced chronic lymphocytic leukemi…

In this edition, surgery confers higher 5-year survival rates than radiotherapy; first-line combination extends PFS in lung cancer subgroup; pembrolizumab improves outcomes in early-stage resectable …

In this edition, cross-border partnership takes on survival gap for children with leukemia; ‘paradigm shift’ in transfusion-dependent myelodysplastic syndrome; FDA approves Ayvakit for mastocytosis a…

In this edition, FDA approves supplemental new drug application for Rexulti, early amyloid PET provides high diagnostic confidence, Leqembi reduced biomarkers of Alzheimer’s and more.

Read the full c…

In this edition, we bring you a deep dive on a collaboration that aims to accelerate better treatments for pediatric cancers. Read the full coverage here:

Collaboration aims to ‘truly accelerate be…

In this edition, tumor mutational burden linked to immunotherapy response; toripalimab regimen extends EFS in stage III NSCLC; phase 3 study designed for increasing trial diversity, and more.

Read th…

In this edition, immunotherapy improves survival rates of infants with leukemia; extreme poverty linked to higher risk for relapse among children with ALL; FDA approves allogeneic cell therapy and mo…

In this edition, trichloroethylene may be ‘invisible’ cause of PD, ravulizumab reduces clinical deterioration in generalized myasthenia gravis and more.

Read the full coverage here:

Trichloroethylen…

In this edition, elevated cardiotoxicity risk for Black patients after chemotherapy; CV risk factor disparities in childhood cancer survivors; neural network helps identify potential targets for canc…

In this edition, DNA sequencing could identify patients with high-risk AML; review of major advances and challenges in chronic lymphocytic leukemia; FDA advisory panel backs polatuzumab vedotin and m…

In this edition, ‘paradigm shift’ in non-small cell lung cancer during past decade; osimertinib extends survival in early EGFR-mutated NSCLC; amivantamab shows durable activity in patients with advan…

In this edition, optimal antibiotics timing among inpatients with cancer; inflammation levels linked to survival in acute myeloid leukemia; dexrazoxane confers long-term cardioprotection for pediatri…

In this edition, FDA clears lab blood test for evaluating concussion, marriage linked to lower risk for dementia, FDA approves nasal spray for migraine in adults and more.

Read the full coverage here…

In this edition, outpatient HSCT feasible for older adults; ponatinib for newly diagnosed Ph+ALL; iomab-B may increase transplant access in relapsed/refractory AML and more. Read the full coverage h…

In this edition, nivolumab confers durable survival benefit; global economic cost of cancer estimated to exceed $25 trillion; phase 3 trials of pembrolizumab miss primary endpoints, and more.

Read th…

In this edition, novel T-cell therapy effective against common viruses; FDA approves Brukinsa for chronic lymphocytic leukemia; meeting abstracts show inconsistent toxicity reporting and more. Read …

In this edition, lobectomy alternatives show adverse event profiles; frequent CT scans not linked to better surgery outcomes; FDA approves adjuvant Keytruda, and more. Read the full coverage here:

…

In this edition, addition of tumor treating fields extends OS; atezolizumab-bevacizumab survival rates; screening leads to more stage I, less stage IV disease incidence, and more.

Read the full cover…

In this edition, groups support CMS policy update on colonoscopy; plant-based food intake and CRC research needed; FDA agrees on pediatric study to develop obefazimod and more.

Read the full coverage…

In this edition, NCI director announces breast cancer diagnosis, neoadjuvant chemotherapy regimen in pancreatic cancer, gender harassment is in oncology and more.

Read the full coverage here:

NCI di…